20260619_SCPI_Laporan Informasi dan Fakta Material_32102422.pdf

Dampak kejadian, informasi atau fakta      Secara operasional dan keuangan, tidak terdapat dampak
material tersebut terhadap kegiatan        negatif karena perusahaan memiliki kemampuan pendanaan
operasional, hukum, kondisi keuangan,      mandiri tanpa mencari dana dari masyarakat. Keputusan ini
atau kelangsungan usaha Emiten atau        dievaluasi oleh manajemen untuk meningkatkan efisiensi
Perusahaan Publik                          pengelolaan aset, operasional, dan strategi bisnis jangka
                                           panjang. Dari aspek hukum, perusahaan menyatakan tidak
                                           sedang menghadapi permasalahan hukum, perkara material,
                                           atau tuntutan dari pihak ketiga yang dapat memengaruhi
                                           rencana go private dan delisting ini secara material.
                                           Perusahaan juga tidak memiliki kewajiban hukum untuk
                                           memperoleh izin atau persetujuan terlebih dahulu dari pihak
                                           ketiga sebagai prasyarat pelaksanaan rencana ini, dan tidak
                                           ada keberatan yang diterima dari pihak ketiga hingga saat ini.
                                           Terhadap struktur kepemilikan saham, apabila penawaran
                                           tender sukarela berhasil menyerap seluruh saham publik,
                                           Organon LLC akan menguasai 100% saham perusahaan.
                                           Berdasarkan ketentuan Undang-Undang Perseroan Terbatas
                                           yang mensyaratkan minimal dimiliki oleh dua pihak, Organon
                                           LLC wajib mengalihkan sebagian saham atau mengeluarkan
                                           saham baru kepada pihak lain dalam jangka waktu maksimal
                                           enam bulan setelah kondisi tersebut terjadi. Bagi pemegang
                                           saham publik yang menolak menjual sahamnya, mereka akan
                                           tetap menjadi pemegang saham di perusahaan tertutup
                                           tersebut.

Demikian untuk diketahui.


Hormat Kami,
PT Organon Pharma Indonesia Tbk




Arie Noviandari

approver dua




PT Organon Pharma Indonesia Tbk
Sinarmas MSIG Tower, Lantai 37, unit 102 & 106, Jalan Jenderal Sudirman Kaveling
Telepon : 085951102178, Fax : 021-31107009, https://www.organon.com/indonesia/



Nama Pengirim                     Arie Noviandari

Jabatan                           approver dua
Tanggal dan Waktu                 19-06-2026 11:40

Lampiran                          1. Keterbukaan Informasi_190626.pdf


 Dokumen ini merupakan dokumen resmi PT Organon Pharma Indonesia Tbk yang tidak memerlukan tanda tangan
     karena dihasilkan secara elektronik oleh sistem pelaporan elektronik. PT Organon Pharma Indonesia Tbk
                    bertanggung jawab penuh atas informasi yang tertera didalam dokumen ini.

Go To Indonesian Page

 Letter / Announcement No.            039/CS-OPI/VI/2026

 Issuer Name                          PT Organon Pharma Indonesia Tbk

 Issuer Code                          SCPI

 Attachment                           1

 Subject                              Plan for Status Change - PT Organon Pharma Indonesia Tbk plans to alter its
                                      status from a public company to a private company and delist its shares from
                                      the Indonesia Stock Exchange

The company hereby announce the Material Information or Facts Report as follows

 Name of Issuer or Public Company             PT Organon Pharma Indonesia Tbk

 Business Activities                          Industri Farmasi


 Telephone                                    085951102178

 Faximile                                     021-31107009

 Email Address                                arie.noviandari.arie.noviandari@organon.com


 Date of Event                                19 June 2026

                                              Plan for Status Change - PT Organon Pharma Indonesia Tbk
 Type of Material Information or Facts        plans to alter its status from a public company to a private
                                              company and delist its shares from the Indonesia Stock
                                              Exchange
 Description of Material Information or       PT Organon Pharma Indonesia Tbk plans to change its status
 Facts                                        from a public company to a private company and delist its
                                              shares from the Indonesia Stock Exchange. This plan is based
                                              on several reasons, including the company shares no longer
                                              being actively traded, very low attendance and participation of
                                              public shareholders in general meetings during the past three
                                              years, the company ability to self-finance its operations without
                                              public funds, and alignment with the global restructuring policy
                                              of the Merck Group. In connection with this plan, the
                                              controlling shareholder, Organon LLC, will conduct a Voluntary
                                              Tender Offer to purchase up to 43,664 public shares or
                                              1.213% of the total paid-up capital at a premium price of
                                              Rp100.000 per share. This offer price is significantly higher
                                              than the historical average daily high price over the last twelve
                                              months, which was Rp32.063 per share. This plan requires the
                                              approval of Independent Shareholders through an
                                              Extraordinary General Meeting of Shareholders scheduled for
                                              June 23, 2026.

 Impact of event, material information or     Operationally and financially, there is no negative impact as
 facts towards Issuers or Public              the company is fully capable of self-funding its activities
 Company’s operational activities, legal,     without public capital market support. The management
 financial condition, or going concern        evaluates that this decision will improve the efficiency of asset
                                              management, operations, and long-term business strategy
                                              implementation. From a legal standpoint, the company
                                              confirms that it is not facing any lawsuits, material legal cases,
                                              or third-party claims that could materially affect the go private
                                              and delisting plan. There is no legal obligation to obtain prior
                                              approval from third parties as a prerequisite for this plan, and
                                              no objections have been received. Regarding the shareholding
                                              structure, if the tender offer successfully acquires all public
                                              shares, Organon LLC will directly own 100% of the company.
                                              Under the Indonesian Company Law, which requires a limited
                                              liability company to have at least two shareholders, Organon
                                              LLC must transfer a portion of its shares or issue new shares
                                              to another party within a maximum period of six months after
                                              the 100% ownership occurs. Public shareholders who choose
                                              not to sell their shares will remain shareholders in the private
                                              company.

Thus to be informed accordingly.


Respectfully,
PT Organon Pharma Indonesia Tbk




Arie Noviandari

approver dua




PT Organon Pharma Indonesia Tbk
Sinarmas MSIG Tower, Lantai 37, unit 102 & 106, Jalan Jenderal Sudirman Kaveling
Phone : 085951102178, Fax : 021-31107009, https://www.organon.com/indonesia/



Sender Name                          Arie Noviandari

Function                             approver dua

Date and Time                        19-06-2026 11:40

Attachment                          1. Keterbukaan Informasi_190626.pdf


   This is an official document of PT Organon Pharma Indonesia Tbk that does not require a signature as it was
 generated electronically by the electronic reporting system. PT Organon Pharma Indonesia Tbk is fully responsible
                                  for the information contained within this document.